PRESS RELEASE published on 06/21/2024 at 07:00, 3 months 7 days ago Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Sanofi presents new data on ALTUVIIIO and fitusiran at ISTH Congress, showcasing potential first- and best-in-class treatments for hemophilia. Fitusiran NDA under FDA review with PDUFA date of March 28, 2025 Sanofi ALTUVIIIO Fitusiran Hemophilia ISTH Congress
BRIEF published on 06/12/2024 at 20:24, 3 months 16 days ago Sanofi: Information on voting rights and shares - May 2024 Voting Rights Investors Actions Sanofi May 2024
PRESS RELEASE published on 06/12/2024 at 20:19, 3 months 16 days ago Sanofi: Information concerning the total number of voting rights and shares – May 2024 Sanofi discloses total number of voting rights and shares as per French commercial code and stock market authority regulations. Details available on Sanofi's website Voting Rights French Commercial Code Shares Sanofi Stock Market Authority
BRIEF published on 06/03/2024 at 22:20, 3 months 25 days ago Phase III study: Sarclisa improves progression-free survival of patients with multiple myeloma Multiple Myeloma Sarclisa ASCO Phase III Study Progression-free Survival
PRESS RELEASE published on 06/03/2024 at 22:15, 3 months 25 days ago Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa in combo with VRd significantly enhances progression-free survival in newly diagnosed transplant-ineligible multiple myeloma in phase 3 study at ASCO. Full data published in NEJM Multiple Myeloma Phase 3 Sarclisa Progression-free Survival VRd
BRIEF published on 05/31/2024 at 12:05, 3 months 28 days ago Sanofi Launches 2024 Global Employee Stock Purchase Plan Financial Investment Sanofi Employee Stock Purchase Plan Action 2024 Global Participation
PRESS RELEASE published on 05/31/2024 at 12:00, 3 months 28 days ago Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
BRIEF published on 05/31/2024 at 07:10, 3 months 28 days ago CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD Sanofi COPD Dupixent CHMP Supply
PRESS RELEASE published on 05/31/2024 at 07:05, 3 months 28 days ago Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation
BRIEF published on 05/30/2024 at 15:06, 3 months 29 days ago Sanofi Completes Acquisition of Inhibrx, Inc. Acquisition Sanofi Rare Diseases Inhibrx SAR447537
Published on 09/28/2024 at 02:06, 22 hours 19 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 22 hours 25 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 22 hours 25 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 10 hours 24 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 1 hour ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 2 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 5 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 6 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 6 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024